{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:47:04Z","timestamp":1794008824279,"version":"4.8.0"},"reference-count":46,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Elderly patients are a special category of patients, due to the physiological changes induced by age, the great number of comorbidities and drug treatment and last, but not least, to the cognitive dysfunction frequently encountered in this population. Cardiovascular disease is the most important cause of morbidity and mortality in elderly individuals worldwide. The rate of cardiovascular events increases after 65 years in men and after 75 years in women. Myocardial infarction and stroke are the leading disorders caused by atherosclerosis, that lead to death or functional incapacity. Elderly people have a greater risk to develop atherosclerotic cardiovascular disease. The incidence and prevalence of atherosclerosis increase with age and the number of cardiovascular events is higher in elderly patients. The most efficient treatment against atherosclerosis is the treatment with statins, that has been shown to decrease the risk both of stroke and coronary artery disease in all age groups. The advantages of the treatment become evident after at least one year of treatment. Primary prevention is the most important way of preventing cardiovascular disease in elderly individuals, by promoting a healthy lifestyle and reducing the risk factors. Secondary prevention after a stroke or myocardial infarction includes mandatory a statin, to diminish the risk of a recurrent cardiovascular event. The possible side effects of statin therapy are diabetes mellitus, myopathy, and rhabdomyolysis, hepatotoxicity. The side effects of the treatment are more likely to occur in elderly patients, due to their multiple associated comorbidities and drugs that may interact with statins. In elderly people, the benefits and disadvantages of the treatment with statins should be put in balance, especially in those receiving high doses of statins.<\/jats:p>","DOI":"10.3390\/medicina55110721","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T05:18:26Z","timestamp":1572499106000},"page":"721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Treatment with Statins in Elderly Patients"],"prefix":"10.3390","volume":"55","author":[{"given":"Ruxandra-Nicoleta","family":"Horodinschi","sequence":"first","affiliation":[{"name":"University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"},{"name":"Clinical Emergency Hospital of Bucharest, 14461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-9470","authenticated-orcid":false,"given":"Ana Maria Alexandra","family":"Stanescu","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-260X","authenticated-orcid":false,"given":"Ovidiu Gabriel","family":"Bratu","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"},{"name":"Academy of Romanian Scientists, Emergency University Central Military Hospital, 010825 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0555-526X","authenticated-orcid":false,"given":"Anca","family":"Pantea Stoian","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel George","family":"Radavoi","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"},{"name":"Clinical Hospital \u201cProf. Dr. Th. Burghele\u201d, 050659 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-260X","authenticated-orcid":false,"given":"Camelia Cristina","family":"Diaconu","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy \u201cCarol Davila\u201d, 020021 Bucharest, Romania"},{"name":"Clinical Emergency Hospital of Bucharest, 14461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/01.STR.0000254602.58896.d2","article-title":"Is it time for a cardiovascular primary prevention trial in the elderly?","volume":"38","author":"Robinson","year":"2007","journal-title":"Stroke"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.678300","article-title":"Statin therapy and the elderly. SAGE advice?","volume":"115","author":"Gotto","year":"2007","journal-title":"Circulation."},{"key":"ref_3","first-page":"1099","article-title":"Elderly peoples\u2019 perception of young people\u2014A preliminary study","volume":"42","author":"Cybulski","year":"2013","journal-title":"Iran. J. Public Health"},{"key":"ref_4","unstructured":"Hughes, S. (2019, August 23). Statin benefits in the elderly: New meta-analysis. Medscape. Available online: https:\/\/www.medscape.com\/viewarticle\/908563?fbclid=IwAR2qQSROFcwn5QjK93t9j0-JPL0_8Dwaemq84BhgiPs1BGc1-wZw4wSYzzc#vp_3."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jacc.2017.10.080","article-title":"Primary prevention with statins in the elderly","volume":"71","author":"Mortensen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group (2002). MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/dom.13701","article-title":"The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of \u201ereal world\u201d practice in people with diabetes","volume":"21","author":"Robinson","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.007535","article-title":"Projected real-worls effectiveness of using aggressive low-density lipoprotein cholesterol targets among elderly statin users following acute coronary syndromes in Canada","volume":"7","author":"Alter","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCOUTCOMES.109.868299","article-title":"The JUPITER trial: Results, controversies, and implications for prevention","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular risk","volume":"374","author":"Yusuf","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"(2019, August 15). Cardiovascular disease: risk assessment and reduction, including lipid modification. Available online: https:\/\/www.nice.org.uk\/guidance\/cg181."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_16","unstructured":"Bartol, T.G. (2019, August 10). Statins in the Elderly: Evidence-Based or Not? Medscape. Available online: https:\/\/www.medscape.com\/viewarticle\/893440?fbclid=IwAR3UTOANwsRTYBQKERKQXylf49JeTJIi0AH-XZDBfsh0_s1xRnwIf7eI-PE."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1161\/STROKEAHA.110.580209","article-title":"Ischemic stroke and secondary prevention in clinical practice","volume":"41","author":"Asberg","year":"2010","journal-title":"Stroke"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE)","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1532-5415.2005.00635.x","article-title":"Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: Evidence for an age-statin interaction","volume":"54","author":"Foody","year":"2006","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006). High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med., 355, 549\u2013559.","DOI":"10.1056\/NEJMoa061894"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","article-title":"Treating to New Targets (TNT) Study: Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?","volume":"93","author":"Waters","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/01.STR.0000183623.28144.32","article-title":"Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients","volume":"36","author":"Kennedy","year":"2005","journal-title":"Stroke"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jvs.2005.08.039","article-title":"3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy","volume":"42","author":"McGirt","year":"2005","journal-title":"J. Vasc. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association between use of statins and mortality in patients with heart failure and ejection fraction of \u226550%","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/CIRCULATIONAHA.105.591446","article-title":"Statins and mortality among elderly patients hospitalized with heart failure","volume":"113","author":"Foody","year":"2006","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group (2007). Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg., 45, 645.","DOI":"10.1016\/j.jvs.2006.12.054"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"key":"ref_30","unstructured":"(2013). KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl., 3, 263\u2013264."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","article-title":"KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD","volume":"65","author":"Sarnak","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events. A scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2007.06.034","article-title":"Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors","volume":"154","author":"Bowman","year":"2007","journal-title":"Am. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_35","unstructured":"Harrison, P. (2019, July 23). Statins increase diabetes risk by up to 50% in older women. Medscape. Available online: https:\/\/www.medscape.com\/viewarticle\/877626?fbclid=IwAR35yzksw3SAyfJYS6lBTWiPtXwCvqfVzvfLsfuYuQwuozhg5f_ur1yBx9I."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins","volume":"6","author":"Naci","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland coronary prevention study","volume":"357","author":"Ford","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCOUTCOMES.111.000015","article-title":"Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins","volume":"6","author":"Ko","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.diabres.2016.07.004","article-title":"The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study","volume":"120","author":"Farmer","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3132\/dvdr.2008.029","article-title":"The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"5","author":"Newman","year":"2008","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial","volume":"361","author":"Lindholm","year":"2003","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/0002-9343(91)90053-Z","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results, IV: Additional perspectives on the tolerability of lovastatin","volume":"91","author":"Dujovne","year":"1991","journal-title":"Am. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/STROKEAHA.117.017358","article-title":"Use of statins and outcomes in intracerebral hemorrhage patients","volume":"48","author":"Siddiqui","year":"2017","journal-title":"Stroke"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/CIRCULATIONAHA.111.055269","article-title":"Statins and intracerebral hemorrhage","volume":"124","author":"Hackam","year":"2011","journal-title":"Circulation"},{"key":"ref_45","unstructured":"(2019, July 19). NICE Clinical Guidelines (UK) No. 181. Lipid Modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK268945\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Armitage","year":"2019","journal-title":"Lancet"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/11\/721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:37Z","timestamp":1760189437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/11\/721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["medicina55110721"],"URL":"https:\/\/doi.org\/10.3390\/medicina55110721","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,30]]}}}